February 4, 2016 – MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing. MorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.
